Literature DB >> 15855821

Treating patients with autoimmune pancreatitis: results from a long-term follow-up study.

Terumi Kamisawa1, Masami Yoshiike, Naoto Egawa, Hitoshi Nakajima, Kouji Tsuruta, Atsutake Okamoto.   

Abstract

BACKGROUND: Steroid therapy is currently common treatment for autoimmune pancreatitis (AIP); however, indications of steroid therapy have yet to be established, and the clinical course after steroid therapy is unknown.
METHODS: A total of 23 patients with AIP were subdivided into 4 groups according to the initial treatments undertaken. They were treated with pancreatoduodenectomy on suspicion of pancreatic tumor in 6 patients, choledochoduodenostomy with pancreatic biopsy in 4 patients, supportive therapy in 3 patients, and steroid therapy in 10 patients. Clinical course of AIP in each group was examined.
RESULTS: Prognosis of the AIP patients is almost good except for the 2 patients who progressed to pancreatic insufficiency after resection. Two patients without jaundice improved spontaneously. Steroid therapy was effective in all patients treated, but pancreatic atrophy developed in 5 of these patients. Steroid therapy improved insulin secretion and glycemic control in 4 of 7 diabetes mellitus (DM) patients.
CONCLUSION: To avoid futile surgery, in relatively elderly male patients with obstructive jaundice suggestive of pancreatic carcinoma, preoperative clinical suspicion of AIP is mandatory. Indications of steroid therapy for AIP are thought to be obstructive jaundice due to stenosis of the bile duct, other associated systemic autoimmune, and DM coincidental with AIP.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15855821     DOI: 10.1159/000085277

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  42 in total

Review 1.  Autoimmune pancreatitis and IgG4-related systemic diseases.

Authors:  Lizhi Zhang; Thomas C Smyrk
Journal:  Int J Clin Exp Pathol       Date:  2010-05-25

Review 2.  Optimising corticosteroid treatment for autoimmune pancreatitis.

Authors:  Amaar Ghazale; Suresh T Chari
Journal:  Gut       Date:  2007-12       Impact factor: 23.059

Review 3.  Autoimmune pancreatitis in Japan: overview and perspective.

Authors:  Tooru Shimosegawa; Atsushi Kanno
Journal:  J Gastroenterol       Date:  2009-04-18       Impact factor: 7.527

Review 4.  Etiopathogenesis of primary sclerosing cholangitis.

Authors:  Roger Chapman; Sue Cullen
Journal:  World J Gastroenterol       Date:  2008-06-07       Impact factor: 5.742

5.  Autoimmune pancreatitis with associated ulcerative colitis in a teenager.

Authors:  Carolina Isabel Gouveia; Laura Oliveira; António P Campos; José Cabral
Journal:  BMJ Case Rep       Date:  2018-12-13

6.  Recent advances in autoimmune pancreatitis.

Authors:  Kazuichi Okazaki; Kazushige Uchida; Toshiro Fukui; Mitsunobu Matsushita; Makoto Takaoka
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-06

7.  Autoimmune pancreatitis: functional and morphological recovery after steroid therapy.

Authors:  László Czakó; Eva Hegyközi; Attila Pálinkás; János Lonovics
Journal:  World J Gastroenterol       Date:  2006-03-21       Impact factor: 5.742

8.  Pyogenic liver abscess after choledochoduodenostomy for biliary obstruction caused by autoimmune pancreatitis.

Authors:  Nobuyuki Toshikuni; Kyohei Kai; Shizo Sato; Motoko Kitano; Masayoshi Fujisawa; Hiroaki Okushin; Kazuhiko Morii; Shinjiro Takagi; Masahiro Takatani; Hirofumi Morishita; Koichi Uesaka; Shiro Yuasa
Journal:  World J Gastroenterol       Date:  2006-10-21       Impact factor: 5.742

Review 9.  [Autoimmune pancreatitis].

Authors:  A Schneider; J M Löhr
Journal:  Internist (Berl)       Date:  2009-03       Impact factor: 0.743

Review 10.  A new conceptualization for Mikulicz's disease as an IgG4-related plasmacytic disease.

Authors:  Motohisa Yamamoto; Hiroki Takahashi; Mikiko Ohara; Chisako Suzuki; Yasuyoshi Naishiro; Hiroyuki Yamamoto; Yasuhisa Shinomura; Kohzoh Imai
Journal:  Mod Rheumatol       Date:  2006-12-20       Impact factor: 3.023

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.